Abstract
The quintessential clinical diagnostic phenotype of human hypertrophic cardiomyopathy (HCM) is primary cardiac hypertrophy. Cardiac hypertrophy is also a major determinant of mortality and morbidity including the risk of sudden cardiac death (SCD) in patients with HCM. Reversal and attenuation of cardiac hypertrophy and its accompanying fibrosis is expected to improve morbidity as well as decrease the risk of SCD in patients with HCM.The conventionally used pharmacological agents in treatment of patients with HCM have not been shown to reverse or attenuate established cardiac hypertrophy and fibrosis. An effective treatment of HCM has to target the molecular mechanisms that are involved in the pathogenesis of the phenotype. Mechanistic studies suggest that cardiac hypertrophy in HCM is secondary to activation of various hypertrophic signaling molecules and, hence, is potentially reversible. The hypothesis is supported by the results of genetic and pharmacological interventions in animal models. The results have shown potential beneficial effects of angiotensin II receptor blocker losartan, mineralocorticoid receptor blocker spironolactone, 3-hydroxy-3-methyglutaryl-coenzyme A reductase inhibitors simvastatin and atorvastatin, and most recently, N-acetylcysteine (NAC) on reversal or prevention of hypertrophy and fibrosis in HCM. The most promising results have been obtained with NAC, which through multiple thiol-responsive mechanisms completely reversed established cardiac hypertrophy and fibrosis in three independent studies. Pilot studies with losartan and statins in humans have established the feasibility of such studies. The results in animal models have firmly established the reversibility of established cardiac hypertrophy and fibrosis in HCM and have set the stage for advancing the findings in the animal models to human patients with HCM through conducting large-scale efficacy studies.
Similar content being viewed by others
References
Arad, M., Maron, B. J., Gorham, J. M., Johnson, W. H., Jr., Saul, J. P., Perez-Atayde, A. R., et al. (2005). Glycogen storage diseases presenting as hypertrophic cardiomyopathy. New England Journal of Medicine, 352, 362–372.
Araujo, A. Q., Arteaga, E., Ianni, B. M., Buck, P. C., Rabello, R., & Mady, C. (2005). Effect of Losartan on left ventricular diastolic function in patients with nonobstructive hypertrophic cardiomyopathy. American Journal of Cardiology, 96, 1563–1567.
Bauersachs, J., Stork, S., Kung, M., Waller, C., Fidler, F., Hoyer, C., et al. (2007). HMG CoA reductase inhibition and left ventricular mass in hypertrophic cardiomyopathy: a randomized placebo-controlled pilot study. European Journal of Clinical Investigation, 37, 852–859.
Benjamin, E. J., & Levy, D. (1999). Why is left ventricular hypertrophy so predictive of morbidity and mortality? American Journal of the Medical Sciences, 317, 168–175.
Bentley, D. R., Balasubramanian, S., Swerdlow, H. P., Smith, G. P., Milton, J., Brown, C. G., et al. (2008). Accurate whole human genome sequencing using reversible terminator chemistry. Nature, 456, 53–59.
Blanchard, E., Seidman, C., Seidman, J. G., LeWinter, M., & Maughan, D. (1999). Altered crossbridge kinetics in the alphaMHC403/+ mouse model of familial hypertrophic cardiomyopathy. Circulation Research, 84, 475–483.
Boltwood, C. M., Jr., Chien, W., & Ports, T. (2004). Ventricular tachycardia complicating alcohol septal ablation. New England Journal of Medicine, 351, 1914–1915.
Chen, M. S., Xu, F. P., Wang, Y. Z., Zhang, G. P., Yi, Q., Zhang, H. Q., et al. (2004). Statins initiated after hypertrophy inhibit oxidative stress and prevent heart failure in rats with aortic stenosis. Journal of Molecular and Cellular Cardiology, 37, 889–896.
Chimenti, C., Pieroni, M., Morgante, E., Antuzzi, D., Russo, A., Russo, M. A., et al. (2004). Prevalence of fabry disease in female patients with late-onset hypertrophic cardiomyopathy. Circulation, 110, 1047–1053.
De Windt, L. J., Lim, H. W., Haq, S., Force, T., & Molkentin, J. D. (2000). Calcineurin promotes protein kinase C and c-Jun NH2-terminal kinase activation in the heart. Cross-talk between cardiac hypertrophic signaling pathways. Journal of Biological Chemistry, 275, 13571–13579.
Delbosc, S., Cristol, J. P., Descomps, B., Mimran, A., & Jover, B. (2002). Simvastatin prevents angiotensin II-induced cardiac alteration and oxidative stress. Hypertension, 40, 142–147.
Demedts, M., Behr, J., Buhl, R., Costabel, U., Dekhuijzen, R., Jansen, H. M., et al. (2005). High-Dose acetylcysteine in idiopathic pulmonary fibrosis. New England Journal of Medicine, 353, 2229–2242.
Ding, B., Price, R. L., Borg, T. K., Weinberg, E. O., Halloran, P. F., & Lorell, B. H. (1999). Pressure overload induces severe hypertrophy in mice treated with cyclosporine, an inhibitor of calcineurin. Circulation Research, 84, 729–734.
Elliott, P. M., Gimeno, B., Jr., Mahon, N. G., Poloniecki, J. D., & McKenna, W. J. (2001). Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet, 357, 420–424.
Fatkin, D., McConnell, B. K., Mudd, J. O., Semsarian, C., Moskowitz, I. G., Schoen, F. J., et al. (2000). An abnormal Ca(2+) response in mutant sarcomere protein-mediated familial hypertrophic cardiomyopathy. Journal of Clinical Investigation, 106, 1351–1359.
Flores-Ramirez, R., Lakkis, N. M., Middleton, K. J., Killip, D., Spencer, W. H., 3rd, & Nagueh, S. F. (2001). Echocardiographic insights into the mechanisms of relief of left ventricular outflow tract obstruction after nonsurgical septal reduction therapy in patients with hypertrophic obstructive cardiomyopathy. Journal of the American College of Cardiology, 37, 208–214.
Fujita, H., Sugiura, S., Momomura, S., Omata, M., Sugi, H., & Sutoh, K. (1997). Characterization of mutant myosins of Dictyostelium discoideum equivalent to human familial hypertrophic cardiomyopathy mutants. Molecular force level of mutant myosins may have a prognostic implication. Journal of Clinical Investigation, 99, 1010–1015.
Gaasch, W. H., & Zile, M. R. (2004). Left ventricular diastolic dysfunction and diastolic heart failure. Annual Review of Medicine, 55(373–94), 373–394.
Georgakopoulos, D., Christe, M. E., Giewat, M., Seidman, C. M., Seidman, J. G., & Kass, D. A. (1999). The pathogenesis of familial hypertrophic cardiomyopathy: early and evolving effects from an alpha-cardiac myosin heavy chain missense mutation [see comments]. Natural Medicines, 5, 327–330.
Haider, A. W., Larson, M. G., Benjamin, E. J., & Levy, D. (1998). Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. Journal of the American College of Cardiology, 32, 1454–1459.
Haim, T. E., Dowell, C., Diamanti, T., Scheuer, J., & Tardiff, J. C. (2007). Independent FHC-related cardiac troponin T mutations exhibit specific alterations in myocellular contractility and calcium kinetics. Journal of Molecular and Cellular Cardiology, 42, 1098–1110.
Harada, K., & Potter, J. D. (2004). Familial hypertrophic cardiomyopathy mutations from different functional regions of troponin T result in different effects on the pH and Ca2+ sensitivity of cardiac muscle contraction. Journal of Biological Chemistry, 279, 14488–14495.
Harada, K., Takahashi-Yanaga, F., Minakami, R., Morimoto, S., & Ohtsuki, I. (2000). Functional consequences of the deletion mutation deltaGlu160 in human cardiac troponin T. Journal of Biochemistry, 127, 263–268.
Hernandez, O. M., Szczesna-Cordary, D., Knollmann, B. C., Miller, T., Bell, M., Zhao, J., et al. (2005). F110I and R278C troponin T mutations that cause familial hypertrophic cardiomyopathy affect muscle contraction in transgenic mice and reconstituted human cardiac fibers. Journal of Biological Chemistry, 280, 37183–37194.
Ho, C. Y., Sweitzer, N. K., McDonough, B., Maron, B. J., Casey, S. A., Seidman, J. G., et al. (2002). Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy. Circulation, 105, 2992–2997.
Hori, Y., Ueda, M., Nakayama, T., Saegusa, N., Uehara, M., Lee, K., et al. (2007). Occurrence of de novo sustained monomorphic ventricular tachycardia induced after percutaneous transluminal alcohol septal myocardial ablation for hypertrophic obstructive cardiomyopathy. International Journal of Cardiology, 119, 403–407.
Hoshikawa, Y., Ono, S., Suzuki, S., Tanita, T., Chida, M., Song, C., et al. (2001). Generation of oxidative stress contributes to the development of pulmonary hypertension induced by hypoxia. Journal of Applied Physiology, 90, 1299–1306.
Indolfi, C., Di Lorenzo, E., Perrino, C., Stingone, A. M., Curcio, A., Torella, D., et al. (2002). Hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin prevents cardiac hypertrophy induced by pressure overload and inhibits p21ras activation. Circulation, 106, 2118–2124.
Kim, J. I., Ju, Y. S., Park, H., Kim, S., Lee, S., Yi, J. H., et al. (2009). A highly annotated whole-genome sequence of a Korean individual. Nature, 460, 1011–1015.
Kitaoka, H., Kubo, T., Okawa, M., Hitomi, N., Furuno, T., & Doi, Y. L. (2006). Left ventricular remodeling of hypertrophic cardiomyopathy: longitudinal observation in rural community. Circulation, 70, 1543–1549.
Knoll, R., Hoshijima, M., Hoffman, H. M., Person, V., Lorenzen-Schmidt, I., Bang, M. L., et al. (2002). The cardiac mechanical stretch sensor machinery involves a Z disc complex that is defective in a subset of human dilated cardiomyopathy. Cell, 111, 943–955.
Kopp, J., Seyhan, H., Muller, B., Lanczak, J., Pausch, E., Gressner, A. M., et al. (2006). N-acetyl-L-cysteine abrogates fibrogenic properties of fibroblasts isolated from Dupuytren’s disease by blunting TGF-beta signalling. Journal of Cellular and Molecular Medicine, 10, 157–165.
Krumholz, H. M., Larson, M., & Levy, D. (1995). Prognosis of left ventricular geometric patterns in the Framingham Heart Study. Journal of the American College of Cardiology, 25, 879–884.
Levy, D., Garrison, R. J., Savage, D. D., Kannel, W. B., & Castelli, W. P. (1990). Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. New England Journal of Medicine, 322, 1561–1566.
Levy, S., Sutton, G., Ng, P. C., Feuk, L., Halpern, A. L., Walenz, B. P., et al. (2007). The diploid genome sequence of an individual human. PLoS Biology, 5, e254.
Liao, J. K., & Laufs, U. (2005). Pleiotropic effects of statins. Annual Review of Pharmacology and Toxicology, 45, 89–118.
Lim, D. S., Lutucuta, S., Bachireddy, P., Youker, K., Evans, A., Entman, M., et al. (2001). Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation, 103, 789–791.
Lim, H. W., De Windt, L. J., Mante, J., Kimball, T. R., Witt, S. A., Sussman, M. A., et al. (2000). Reversal of cardiac hypertrophy in transgenic disease models by calcineurin inhibition. Journal of Molecular and Cellular Cardiology, 32, 697–709.
Liu, D. D., Kao, S. J., & Chen, H. I. (2008). N-acetylcysteine attenuates acute lung injury induced by fat embolism. Critical Care Medicine, 36, 565–571.
Liu, R. M., Liu, Y., Forman, H. J., Olman, M., & Tarpey, M. M. (2004). Glutathione regulates transforming growth factor-{beta}-stimulated collagen production in fibroblasts. American Journal of Physiology. Lung Cellular and Molecular Physiology, 286, L121–L128.
Lombardi, R., Bell, A., Senthil, V., Sidhu, J., Noseda, M., Roberts, R., et al. (2008). Differential interactions of thin filament proteins in two cardiac troponin T mouse models of hypertrophic and dilated cardiomyopathies. Cardiovascular Research, 79, 109–117.
Lombardi, R., Rodriguez, G., Chen, S. N., Ripplinger, C. M., Li, W., Chen, J., et al. (2009). Resolution of established cardiac hypertrophy and fibrosis and prevention of systolic dysfunction in a transgenic rabbit model of human cardiomyopathy through thiol-sensitive mechanisms. Circulation, 119, 1398–1407.
Lowey, S., Lesko, L. M., Rovner, A. S., Hodges, A. R., White, S. L., Low, R. B., et al. (2008). Functional effects of the hypertrophic cardiomyopathy R403Q mutation are different in an alpha- or beta-myosin heavy chain backbone. Journal of Biological Chemistry, 283, 20579–20589.
Luo, J. D., Zhang, W. W., Zhang, G. P., Guan, J. X., & Chen, X. (1999). Simvastatin inhibits cardiac hypertrophy and angiotensin-converting enzyme activity in rats with aortic stenosis. Clinical and Experimental Pharmacology and Physiology, 26, 903–908.
Lutucuta, S., Tsybouleva, N., Ishiyama, M., Defreitas, G., Wei, L., Carabello, B., et al. (2004). Induction and reversal of cardiac phenotype of human hypertrophic cardiomyopathy mutation cardiac troponin T-Q92 in switch on-switch off bigenic mice. Journal of the American College of Cardiology, 44, 2221–2230.
Marian, A. J. (2000). Pathogenesis of diverse clinical and pathological phenotypes in hypertrophic cardiomyopathy. Lancet, 355, 58–60.
Marian, A. J. (2007). Hypertrophic cardiomyopathy. In C. C. Liew & V. Dzau (Eds.), Cardiovascular genetics and genomics for the gardiologist (pp. 30–54). Hoboken, NJ:Wiley-Blackwell.
Marian, A. J. (2008). Clinical implications of the “personal” genome. Current Atherosclerosis Reports, 10, 361–363.
Marian, A. J. (2008). Genetic determinants of cardiac hypertrophy. Current Opinion in Cardiology, 23, 199–205.
Marian, A. J. (2008). Hypertrophic Cardiomyopathy. In R. E. Rackel & E. T. Bope (Eds.), Conn’s current therapy (pp. 333–335). Philadelphia: Saunders-Elsevier.
Marian, A. J., Senthil, V., Chen, S. N., & Lombardi, R. (2006). Antifibrotic effects of antioxidant N-acetylcysteine in a mouse model of human hypertrophic cardiomyopathy mutation. Journal of the American College of Cardiology, 47, 827–834.
Maron, B. J. (2002). Hypertrophic cardiomyopathy: a systematic review. Journal of the American Medical Association, 287, 1308–1320.
Maron, B. J., Dearani, J. A., Ommen, S. R., Maron, M. S., Schaff, H. V., Gersh, B. J., et al. (2004). The case for surgery in obstructive hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 44, 2044–2053.
Maron, B. J., Doerer, J. J., Haas, T. S., Tierney, D. M., & Mueller, F. O. (2009). Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 1980–2006. Circulation, 119, 1085–1092.
Maron, B. J., Shen, W. K., Link, M. S., Epstein, A. E., Almquist, A. K., Daubert, J. P., et al. (2000). Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. New England Journal of Medicine, 342, 365–373.
Maron, B. J., Spirito, P., Shen, W. K., Haas, T. S., Formisano, F., Link, M. S., et al. (2007). Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. Journal of the American Medical Association, 298, 405–412.
Maron, M. S., Olivotto, I., Zenovich, A. G., Link, M. S., Pandian, N. G., Kuvin, J. T., et al. (2006). Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation, 114, 2232–2239.
Matsumura, Y., Elliott, P. M., Virdee, M. S., Sorajja, P., Doi, Y., & McKenna, W. J. (2002). Left ventricular diastolic function assessed using Doppler tissue imaging in patients with hypertrophic cardiomyopathy: relation to symptoms and exercise capacity. Heart, 87, 247–251.
McGregor, J. B., Rahman, A., Rosanio, S., Ware, D., Birnbaum, Y., & Saeed, M. (2004). Monomorphic ventricular tachycardia: a late complication of percutaneous alcohol septal ablation for hypertrophic cardiomyopathy. American Journal of the Medical Sciences, 328, 185–188.
McLeod, C. J., Ommen, S. R., Ackerman, M. J., Weivoda, P. L., Shen, W. K., Dearani, J. A., et al. (2007). Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive hypertrophic cardiomyopathy. European Heart Journal, 28, 2583–2588.
McMahon, C. J., Nagueh, S. F., Pignatelli, R. H., Denfield, S. W., Dreyer, W. J., Price, J. F., et al. (2004). Characterization of left ventricular diastolic function by tissue Doppler imaging and clinical status in children with hypertrophic cardiomyopathy. Circulation, 109, 1756–1762.
McTaggart, D. R. (2004). Diltiazem reverses tissue Doppler velocity abnormalities in pre-clinical hypertrophic cardiomyopathy. Heart, Lung & Circulation, 13, 39–40.
Montgomery, D. E., Tardiff, J. C., & Chandra, M. (2001). Cardiac troponin T mutations: correlation between the type of mutation and the nature of myofilament dysfunction in transgenic mice. Journal of Physiology, 536, 583–592.
Morimoto, S., Lu, Q. W., Harada, K., Takahashi-Yanaga, F., Minakami, R., Ohta, M., et al. (2002). Ca(2+)-desensitizing effect of a deletion mutation Delta K210 in cardiac troponin T that causes familial dilated cardiomyopathy. Proceedings of the National Academy of Sciences of the United States of America, 99, 913–918.
Morimoto, S., Nakaura, H., Yanaga, F., & Ohtsuki, I. (1999). Functional consequences of a carboxyl terminal missense mutation Arg278Cys in human cardiac troponin T. Biochemical and Biophysical Research Communications, 261, 79–82.
Morita, H., Seidman, J., & Seidman, C. E. (2005). Genetic causes of human heart failure. Journal of Clinical Investigation, 115, 518–526.
Moriyama, T., Kawada, N., Nagatoya, K., Takeji, M., Horio, M., Ando, A., et al. (2001). Fluvastatin suppresses oxidative stress and fibrosis in the interstitium of mouse kidneys with unilateral ureteral obstruction. Kidney International, 59, 2095–2103.
Nagueh, S. F., Bachinski, L. L., Meyer, D., Hill, R., Zoghbi, W. A., Tam, J. W., et al. (2001). Tissue Doppler imaging consistently detects myocardial abnormalities in patients with hypertrophic cardiomyopathy and provides a novel means for an early diagnosis before and independently of hypertrophy. Circulation, 104, 128–130.
Nagueh, S. F., Chen, S., Patel, R., Tsybouleva, N., Lutucuta, S., Kopelen, H. A., et al. (2004). Evolution of expression of cardiac phenotypes over a 4-year period in the beta-myosin heavy chain-Q403 transgenic rabbit model of human hypertrophic cardiomyopathy. Journal of Molecular and Cellular Cardiology, 36, 663–673.
Nagueh, S. F., Kopelen, H. A., Lim, D. S., Zoghbi, W. A., Quinones, M. A., Roberts, R., et al. (2000). Tissue Doppler imaging consistently detects myocardial contraction and relaxation abnormalities, irrespective of cardiac hypertrophy, in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation, 102, 1346–1350.
Nagueh, S. F., Lakkis, N. M., Middleton, K. J., Spencer, W. H., III, Zoghbi, W. A., & Quinones, M. A. (1999). Doppler estimation of left ventricular filling pressures in patients with hypertrophic cardiomyopathy. Circulation, 99, 254–261.
Nakaura, H., Morimoto, S., Yanaga, F., Nakata, M., Nishi, H., Imaizumi, T., et al. (1999). Functional changes in troponin T by a splice donor site mutation that causes hypertrophic cardiomyopathy. American Journal of Physiology, 277, C225–C232.
Nakaura, H., Yanaga, F., Ohtsuki, I., & Morimoto, S. (1999). Effects of missense mutations Phe110Ile and Glu244Asp in human cardiac troponin T on force generation in skinned cardiac muscle fibers. Journal of Biochemistry (Tokyo), 126, 457–460.
Niimura, H., Bachinski, L. L., Sangwatanaroj, S., Watkins, H., Chudley, A. E., McKenna, W., et al. (1998). Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. New England Journal of Medicine, 338, 1248–1257.
Niimura, H., Patton, K. K., McKenna, W. J., Soults, J., Maron, B. J., Seidman, J. G., et al. (2002). Sarcomere protein gene mutations in hypertrophic cardiomyopathy of the elderly. Circulation, 105, 446–451.
Oi, S., Haneda, T., Osaki, J., Kashiwagi, Y., Nakamura, Y., Kawabe, J., et al. (1999). Lovastatin prevents angiotensin II-induced cardiac hypertrophy in cultured neonatal rat heart cells. European Journal of Pharmacology, 376, 139–148.
Olivotto, I., Gistri, R., Petrone, P., Pedemonte, E., Vargiu, D., & Cecchi, F. (2003). Maximum left ventricular thickness and risk of sudden death in patients with hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 41, 315–321.
Ommen, S. R., Maron, B. J., Olivotto, I., Maron, M. S., Cecchi, F., Betocchi, S., et al. (2005). Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 46, 470–476.
Ommen, S. R., Shah, P. M., & Tajik, A. J. (2008). Left ventricular outflow tract obstruction in hypertrophic cardiomyopathy: past, present and future. Heart, 94, 1276–1281.
Osio, A., Tan, L., Chen, S. N., Lombardi, R., Nagueh, S. F., Shete, S., et al. (2007). Myozenin 2 is a novel gene for human hypertrophic cardiomyopathy. Circulation Research, 100, 766–768.
Ostman-Smith, I., Wettrell, G., & Riesenfeld, T. (1999). A cohort study of childhood hypertrophic cardiomyopathy: improved survival following high-dose beta-adrenoceptor antagonist treatment. Journal of the American College of Cardiology, 34, 1813–1822.
Patel, R., Nagueh, S. F., Tsybouleva, N., Abdellatif, M., Lutucuta, S., Kopelen, H. A., et al. (2001). Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation, 104, 317–324.
Ripplinger, C. M., Li, W., Hadley, J., Chen, J., Rothenberg, F., Lombardi, R., et al. (2007). Enhanced transmural fiber rotation and connexin 43 heterogeneity are associated with an increased upper limit of vulnerability in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation Research, 101, 1049–1057.
Rust, E. M., Albayya, F. P., & Metzger, J. M. (1999). Identification of a contractile deficit in adult cardiac myocytes expressing hypertrophic cardiomyopathy-associated mutant troponin T proteins. Journal of Clinical Investigation, 103, 1459–1467.
Sarikas, A., Carrier, L., Schenke, C., Doll, D., Flavigny, J., Lindenberg, K. S., et al. (2005). Impairment of the ubiquitin-proteasome system by truncated cardiac myosin binding protein C mutants. Cardiovascular Research, 66, 33–44.
Sata, M., & Ikebe, M. (1996). Functional analysis of the mutations in the human cardiac beta-myosin that are responsible for familial hypertrophic cardiomyopathy. Implication for the clinical outcome. Journal of Clinical Investigation, 98, 2866–2873.
Schiffmann, R., Murray, G. J., Treco, D., Daniel, P., Sellos-Moura, M., Myers, M., et al. (2000). Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proceedings of the National Academy of Sciences of the United States of America, 97, 365–370.
Seggewiss, H. (2001). Current status of alcohol septal ablation for patients with hypertrophic cardiomyopathy. Current Cardiology Reports, 3, 160–166.
Seggewiss, H., Gleichmann, U., Faber, L., Fassbender, D., Schmidt, H. K., & Strick, S. (1998). Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: acute results and 3-month follow-up in 25 patients. Journal of the American College of Cardiology, 31, 252–258.
Semsarian, C., Ahmad, I., Giewat, M., Georgakopoulos, D., Schmitt, J. P., McConnell, B. K., et al. (2002). The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model. Journal of Clinical Investigation, 109, 1013–1020.
Senthil, V., Chen, S. N., Tsybouleva, N., Halder, T., Nagueh, S. F., Willerson, J. T., et al. (2005). Prevention of cardiac hypertrophy by atorvastatin in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation Research, 97, 285–292.
Sherrid, M. V., Barac, I., McKenna, W. J., Elliott, P. M., Dickie, S., Chojnowska, L., et al. (2005). Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 45, 1251–1258.
Sirenko, S. G., Potter, J. D., & Knollmann, B. C. (2006). Differential effect of troponin T mutations on the inotropic responsiveness of mouse hearts—role of myofilament Ca2+ sensitivity increase. Journal of Physiology (Online), 575, 201–213.
Solaro, R. J., Varghese, J., Marian, A. J., & Chandra, M. (2002). Molecular mechanisms of cardiac myofilament activation: modulation by pH and a troponin T mutant R92Q. Basic Research in Cardiology, 97(Suppl 1), I102–I110.
Sorajja, P., Valeti, U., Nishimura, R. A., Ommen, S. R., Rihal, C. S., Gersh, B. J., et al. (2008). Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation, 118, 131–139.
Spirito, P., Bellone, P., Harris, K. M., Bernabo, P., Bruzzi, P., & Maron, B. J. (2000). Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. New England Journal of Medicine, 342, 1778–1785.
Sussman, M. A., Lim, H. W., Gude, N., Taigen, T., Olson, E. N., Robbins, J., et al. (1998). Prevention of cardiac hypertrophy in mice by calcineurin inhibition. Science, 281, 1690–1693.
Sweeney, H. L., Feng, H. S., Yang, Z., & Watkins, H. (1998). Functional analyses of troponin T mutations that cause hypertrophic cardiomyopathy: insights into disease pathogenesis and troponin function. Proceedings of the National Academy of Sciences of the United States of America, 95, 14406–14410.
Szczesna, D., Zhang, R., Zhao, J., Jones, M., Guzman, G., & Potter, J. D. (2000). Altered regulation of cardiac muscle contraction by troponin T mutations that cause familial hypertrophic cardiomyopathy. Journal of Biological Chemistry, 275, 624–630.
Taigen, T., De Windt, L. J., Lim, H. W., & Molkentin, J. D. (2000). Targeted inhibition of calcineurin prevents agonist-induced cardiomyocyte hypertrophy. Proceedings of the National Academy of Sciences of the United States of America, 97, 1196–1201.
Takeda, Y., Yoneda, T., Demura, M., Usukura, M., & Mabuchi, H. (2002). Calcineurin inhibition attenuates mineralocorticoid-induced cardiac hypertrophy. Circulation, 105, 677–679.
Takemoto, M., Node, K., Nakagami, H., Liao, Y., Grimm, M., Takemoto, Y., et al. (2001). Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. Journal of Clinical Investigation, 108, 1429–1437.
Takimoto, E., & Kass, D. A. (2007). Role of oxidative stress in cardiac hypertrophy and remodeling. Hypertension, 49, 241–248.
Talreja, D. R., Nishimura, R. A., Edwards, W. D., Valeti, U. S., Ommen, S. R., Tajik, A. J., et al. (2004). Alcohol septal ablation versus surgical septal myectomy: comparison of effects on atrioventricular conduction tissue. Journal of the American College of Cardiology, 44, 2329–2332.
Tam, S. K., Gu, W., Mahdavi, V., & Nadal-Ginard, B. (1995). Cardiac myocyte terminal differentiation. Potential for cardiac regeneration. Annals of the New York Academy of Sciences, 752(72–9), 72–79.
Tanigawa, G., Jarcho, J. A., Kass, S., Solomon, S. D., Vosberg, H. P., Seidman, J. G., et al. (1990). A molecular basis for familial hypertrophic cardiomyopathy: an alpha/beta cardiac myosin heavy chain hybrid gene. Cell, 62, 991–998.
Tardiff, J. C., Factor, S. M., Tompkins, B. D., Hewett, T. E., Palmer, B. M., Moore, R. L., et al. (1998). A truncated cardiac troponin T molecule in transgenic mice suggests multiple cellular mechanisms for familial hypertrophic cardiomyopathy. Journal of Clinical Investigation, 101, 2800–2811.
Tardiff, J. C., Hewett, T. E., Palmer, B. M., Olsson, C., Factor, S. M., Moore, R. L., et al. (1999). Cardiac troponin T mutations result in allele-specific phenotypes in a mouse model for hypertrophic cardiomyopathy. Journal of Clinical Investigation, 104, 469–481.
Tirouvanziam, R., Conrad, C. K., Bottiglieri, T., Herzenberg, L. A., Moss, R. B., & Herzenberg, L. A. (2006). High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis. Proceedings of the National Academy of Sciences of the United States of America, 103, 4628–4633.
Tobacman, L. S., Lin, D., Butters, C., Landis, C., Back, N., Pavlov, D., et al. (1999). Functional consequences of troponin T mutations found in hypertrophic cardiomyopathy. Journal of Biological Chemistry, 274, 28363–28370.
Tsybouleva, N., Zhang, L., Chen, S., Patel, R., Lutucuta, S., Nemoto, S., et al. (2004). Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy. Circulation, 109, 1284–1291.
Wang, J., Wang, W., Li, R., Li, Y., Tian, G., Goodman, L., et al. (2008). The diploid genome sequence of an Asian individual. Nature, 456, 60–65.
Wheeler, D. A., Srinivasan, M., Egholm, M., Shen, Y., Chen, L., McGuire, A., et al. (2008). The complete genome of an individual by massively parallel DNA sequencing. Nature, 452, 872–876.
Wilcox, W. R., Banikazemi, M., Guffon, N., Waldek, S., Lee, P., Linthorst, G. E., et al. (2004). Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. American Journal of Human Genetics, 75, 65–74.
Woo, A., Williams, W. G., Choi, R., Wigle, E. D., Rozenblyum, E., Fedwick, K., et al. (2005). Clinical and echocardiographic determinants of long-term survival after surgical myectomy in obstructive hypertrophic cardiomyopathy. Circulation, 111, 2033–2041.
Xia, Z., Kuo, K. H., Nagareddy, P. R., Wang, F., Guo, Z., Guo, T., et al. (2007). N-acetylcysteine attenuates PKCbeta2 overexpression and myocardial hypertrophy in streptozotocin-induced diabetic rats. Cardiovascular Research, 73, 770–782.
Yamazaki, T., Suzuki, J., Shimamoto, R., Tsuji, T., Ohmoto-Sekine, Y., Ohtomo, K., et al. (2007). A new therapeutic strategy for hypertrophic nonobstructive cardiomyopathy in humans. A randomized and prospective study with an Angiotensin II receptor blocker. International Heart Journal, 48, 715–724.
Yanaga, F., Morimoto, S., & Ohtsuki, I. (1999). Ca2+ sensitization and potentiation of the maximum level of myofibrillar ATPase activity caused by mutations of troponin T found in familial hypertrophic cardiomyopathy. Journal of Biological Chemistry, 274, 8806–8812.
Zafarullah, M., Li, W. Q., Sylvester, J., & Ahmad, M. (2003). Molecular mechanisms of N-acetylcysteine actions. Cellular and Molecular Life Sciences, 60, 6–20.
Zile, M. R., Baicu, C. F., & Gaasch, W. H. (2004). Diastolic heart failure—abnormalities in active relaxation and passive stiffness of the left ventricle. New England Journal of Medicine, 350, 1953–1959.
Zile, M. R., & Brutsaert, D. L. (2002). New concepts in diastolic dysfunction and diastolic heart failure: Part I: diagnosis, prognosis, and measurements of diastolic function. Circulation, 105, 1387–1393.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Marian, A.J. Experimental Therapies in Hypertrophic Cardiomyopathy. J. of Cardiovasc. Trans. Res. 2, 483–492 (2009). https://doi.org/10.1007/s12265-009-9132-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12265-009-9132-7